Highest-materiality recent filing
Surgery Partners to sell Idaho Falls hospitals to Intermountain Health for ~$795M
Transaction values combined facilities at ~$1.15B; Surgery Partners receives ~$795M in total consideration.
Surgery Partners annual meeting: all director nominees re-elected, say-on-pay and auditor ratified
Class II directors Devin O'Reilly, Brent Turner, and Laura L. Forese re-elected with >90M votes for each.
Surgery Partners Q1 revenue $810.9M (+4.5%), net loss $35.9M; reaffirms FY guidance
Revenue $810.9M (+4.5% YoY); same-facility revenue +4.4% on 0.6% case growth and 3.8% revenue per case.
Revenue $885.0M (+2.4% YoY); full-year $3.3B (+6.2%). Same-facility revenue +3.5% Q4.
Surgery Partners subsidiary issues additional $425M of 7.25% Senior Notes due 2032
Surgery Center Holdings issued $425M add-on to existing 7.250% Senior Notes due 2032; total now $1.225B.
Surgery Partners subsidiary prices $425M add-on of 7.250% senior notes due 2032
Issuer Surgery Center Holdings priced $425M aggregate principal of 7.250% senior unsecured notes due 2032.
Surgery Partners subsidiary to offer $425M add-on 7.250% senior notes due 2032
Intent to offer $425M additional 7.250% Senior Notes due 2032, same series as April 2024 issuance.
Oppenheimer joins from Hospital for Special Surgery, where he was Chief Strategy Officer and COO.
Surgery Partners Q3 revenue up 6.6% to $821.5M, net loss $22.7M; FY guidance cut
Revenue $821.5M (+6.6% YoY); same-facility revenue +6.3%, cases +3.4%.
Surgery Partners' National Group President Harrison R. Bane resigns effective Oct 3, 2025
Harrison R. Bane, National Group President, resigns effective October 3, 2025.
Surgery Partners closes $1.383B term loan refinancing; extends maturities to 2030/2028
New $1.383B 2025 Refinancing Term Loans replace existing term loans; maturity extended to Dec 19, 2030.
Surgery Partners Chairman Wayne DeVeydt resigns; Blair Hendrix named new Chairman
Wayne S. DeVeydt resigned as director and Executive Chairman effective August 4, 2025.
Surgery Partners Q2 revenue up 8.4% to $826.2M; Adj EBITDA $129M, up 9%; reaffirms FY2025 guidance
Revenue $826.2M (+8.4% YoY); same-facility revenue +5.1%, same-facility cases +3.4%.
Surgery Partners ends Bain Capital buyout talks; reaffirms 2025 guidance
Special Committee determined that remaining independent provides greater long-term value than Bain Capital's acquisition proposal.
Stockholders re-elected John A. Deane, Teresa DeLuca, M.D., and Wayne S. DeVeydt as Class I directors for three-year terms.
Surgery Partners Q1 revenue up 8.2% to $776M; Adj EBITDA $103.9M (+6.6%); net loss $37.7M
Same-facility revenue +5.2%, same-facility cases +6.5% YoY; revenue per case -1.2%.
Surgery Partners Q4 revenue up 17.5% to $864.4M; Adj EBITDA +15.1%; sets 2025 guidance
Q4 revenue $864.4M (+17.5% YoY); full-year revenue $3.1B (+13.5% YoY).
Surgery Partners receives $25.75/share buyout proposal from Bain Capital; Bain owns ~39%
Bain Capital proposes to acquire all outstanding shares not already owned for $25.75 per share in cash.
Surgery Partners appoints Dr. Laura L. Forese to Board of Directors, effective Jan 10, 2025
Dr. Forese, former EVP and COO of New York-Presbyterian, appointed as independent director.
Surgery Partners Q3 revenue $770.4M (+14.3% YoY); adjusted EBITDA $128.6M (+21.9%)
Revenue $770.4M, +14.3% YoY; same-facility revenue +4.2% on 3.7% case growth.
Surgery Partners dismisses Deloitte, engages EY as auditor
Deloitte & Touche dismissed as independent auditor effective Aug 21, 2024; no adverse opinions or disagreements.
Surgery Partners Q2 revenue +14.2% to $762.1M; raises FY2024 guidance
Revenue $762.1M (+14.2% YoY); same-facility revenue up 9.9%, cases up 3.9%.
Surgery Partners closes $1.4B term loan refinancing, extending maturity to 2030
$1.4B aggregate principal of 2024 Refinancing Term Loans priced at Term SOFR + 2.75% or base rate + 1.75%.
Surgery Partners shareholders approve all four proposals at 2024 annual meeting
Re-elected Class III directors Clifford Adlerz, J. Eric Evans, Blair Hendrix, and Andrew Kaplan.
Surgery Partners Q1 revenue up 7.7% to $717.4M, Adjusted EBITDA $97.5M; raises FY outlook
Net loss $12.4M; Adjusted EBITDA $97.5M (+8.2% YoY); margin 13.6%.
Surgery Partners issues $800M 7.250% notes due 2032, refinances higher-coupon debt
Subsidiary Surgery Center Holdings issued $800M aggregate principal of 7.250% senior unsecured notes due April 15, 2032.
$600M aggregate principal of senior unsecured notes due 2032; interest rate set at pricing.
Surgery Partners prices $800M 7.250% senior notes due 2032 to refinance existing debt
Issuer (Surgery Center Holdings) priced $800M aggregate principal of 7.250% senior unsecured notes due 2032.
Surgery Partners Q4 revenue +4% to $735.4M; FY Adjusted EBITDA $438.1M; guides 2024 revenue >$3B
Q4 revenue $735.4M (+4.0% YoY); full-year revenue $2.74B (+8.0% YoY).
Surgery Partners reaffirms 2023 guidance, projects 2024 Adj. EBITDA >$495M
Reaffirmed 2023 Adjusted EBITDA guidance of $436M-$440M; revenue ~$2.75B.
Surgery Partners enters $1.4B term loan and $703.75M revolver, refinances existing debt
New $1.4B senior secured term loan due 2030 and $703.75M revolving credit facility due 2028.
Surgery Partners selling stockholders offer 8M shares at $33.44; company receives no proceeds
Selling stockholders offering 8,000,000 shares of common stock at $33.44 per share via underwritten offering.
Surgery Partners subsidiary receives commitments for $1.4B new term loan; refinances 2026 debt
New $1.4B senior secured term loan at SOFR+3.50%, maturing 7 years after closing.
Surgery Partners Q3 revenue up 8.6% to $674M; raises FY Adjusted EBITDA guidance to $436-440M
Revenues $674.1M (+8.6% YoY); net loss improved to $4.9M from $25M.
Surgery Partners Q2 revenue $667.6M (+8.5% YoY), EBITDA beat; FY guidance raised
Revenue $667.6M (+8.5% YoY); same-facility revenue +8.3% (~10% adj. for $8M cyber headwind).
Surgery Partners annual meeting re-elects Class II directors, approves say-on-pay, ratifies auditor
Class II directors Maryland, O'Reilly, Turner re-elected with >105M votes each; broker non-votes ~1.5M.
Surgery Partners Q1 revenue up 11.7% to $666.2M, net loss $24.9M, raises 2023 EBITDA guidance >$430M
Revenue $666.2M (+11.7% YoY); same-facility revenue +10.3% (cases +5.3%, revenue per case +4.8%).
Surgery Partners Q4 revenue up 15.9% to $707.1M; sets 2023 EBITDA guidance >$425M
Revenue $707.1M in Q4 (+15.9% YoY); full-year revenue $2.5B (+14.1%).
Surgery Partners reaffirms 2022 revenue and Adj. EBITDA guidance at J.P. Morgan conference
Reaffirms 2022 revenue guidance of $2.50B to $2.55B.
Surgery Partners closes $225M private placement of common stock to Bain affiliates at $24.50/share
Completed private placement of $225M common stock to affiliates of Bain Capital; issued 9,183,673 shares at $24.50/share.
Public offering of 23,469,388 shares at $24.50/share, with option for up to 3,520,408 additional shares.
Surgery Partners Q3 revenue +11% to $620.6M, Adj EBITDA $96.2M, reaffirms FY guidance
Revenue $620.6M (+11.0% YoY); same-facility revenue +5.1% (cases +3.3%, rev/case +1.8%).
Surgery Partners Q2 revenue up 13.3% to $615.4M; Adj EBITDA up 13.4% to $86.1M
Revenue $615.4M vs $543.3M; net loss $18.4M vs $26.9M in prior year quarter.
Surgery Partners stockholders re-elect three Class I directors, approve say-on-pay, ratify Deloitte
John A. Deane re-elected with 76.4M votes for, 9.7M withheld.
Surgery Partners Q1 revenue $596.2M (+16.4%), net income $12.2M; raises FY2022 guidance
Revenue $596.2M (+16.4% YoY); net income $12.2M vs prior-year net loss $31.3M.
Surgery Partners Q4 2021 Adj. EBITDA $114.4M, raises 2022 guidance
Q4 2021 revenue $610.2M (+11.3% YoY); net loss $0.1M; Adj. EBITDA $114.4M (+26.0%, incl. $11.6M CARES grants).
Surgery Partners reaffirms 2021/2022 guidance, appoints David Doherty as CFO
David Doherty appointed EVP & CFO effective Feb 1, 2022, succeeding Thomas Cowhey who resigns Jan 31, 2022.
Surgery Partners increases revolving credit facility by $40M to $210M
Seventh Amendment to credit agreement ups aggregate revolving commitments from $170M to $210M.
Surgery Partners prices public offering of 6M shares at $46.50 per share
Offering of 6,000,000 common shares at $46.50 each; underwriters granted 30-day option for 900,000 additional shares.
Surgery Partners Q3 revenue up 12.7% to $559.2M; raises FY EBITDA guidance to $325-330M
Revenue $559.2M (+12.7% YoY); net loss $22.9M; adjusted EBITDA $76.4M (+25% YoY).
On January 10, 2022, the Company announced the appointment of David T. Doherty to serve as Executive Vice President and Chief Financial Officer of the Company, effective as of February 1, 2022.
Max materiality 0.85 · Median 0.65 · Most common event earnings